News


Nov 02 2015

OticPharma Acquires Novel Otitis Media Program from Otodyne, Inc

IRVINE, Calif. and REHOVOT, Israel, Nov. 2, 2015 /PRNewswire/ — OticPharma, Inc., a privately held specialty pharmaceutical company focused on acquiring and developing innovative therapies for ear, nose, and throat (ENT) disorders, today announced that it has entered into a license agreement with Morristown, New Jersey based drug developer Otodyne, Inc., providing OticPharma with exclusive worldwide […]

Sep 22 2015

OticPharma Announces Key Additions to the Senior Management Team

Christine G. Ocampo named Senior Vice President and Chief Financial Officer Michael P. Cruse named Vice President of Corporate Operations IRVINE, Calif. and REHOVOT, Israel, Sept. 22, 2015 /PRNewswire/ — OticPharma, Ltd., a privately held company focused on acquiring and developing innovative therapies for ear, nose, and throat (ENT) disorders, today announced two new additions to the […]

Sep 03 2015

OticPharma Establishes U.S. Headquarters in Orange County, California

IRVINE, Calif. and REHOVOT, Israel, Sept. 3, 2015 /PRNewswire/ — OticPharma, Ltd., a privately held company focused on acquiring and developing innovative therapies for ear, nose, and throat (ENT) disorders, today announced it has selected the Irvine Company’s Newport Gateway office complex to be the location of its new U.S. headquarters.  OticPharma plans to complete […]

Jul 27 2015

OticPharma Appoints Gregory J. Flesher as Chief Executive Officer

IRVINE, Calif. and REHOVOT, Israel, July 27, 2015 /PRNewswire/ — OticPharma Ltd, a privately held pharmaceutical company focused on developing innovative therapies for ear, nose, and throat disorders, today announced the appointment of Gregory J. Flesher as chief executive officer and member of the company’s board of directors. Mr. Flesher brings more than 20 years […]

Feb 23 2015

OticPharma announces encouraging feedback from a Pre-IND meeting with the Food and Drug Administration (FDA)

REHOVOT, Israel–(BUSINESS WIRE)–OticPharma, a privately held biopharmaceutical company focused on the development of innovative, localized, aerosol foam-based products for Ear, Nose and Throat (ENT) disorders, announces encouraging feedback from a Pre-IND meeting held recently with the FDA concerning the clinical development plan of its lead investigational new drug product, FoamOtic Externa (0.3% Ciprofloxacin). FoamOtic Externa […]